|
|
|
|
In patients with relapsing-remitting multiple sclerosis, both BG-12 regimens, as compared with placebo, significantly reduced the proportion of patients who had a relapse, the annualized relapsed rate, the rate of disability progression, and the number of lesions on MRI. |
|